Jubilant Ingrevia Ltd
JUBLINGREAJubilant Ingrevia Ltd's earnings have outrun its stock. EPS grew +10.7% in a year against a −7.1% price move.
The sharpest disagreement: Promoters moved −6.3 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a confirmed uptrend (8 weeks in) while the P/E sits at the 39th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +41.3% year on year, and 205% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Jubilant Ingrevia Ltd trades at ₹658, in a confirmed uptrend and 8 weeks into that stage. That is −3.9% against its own 200-day average. It sits at 54% of a 52-week range of ₹558 to ₹743. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks.
Today the stock is in a confirmed uptrend — week 8 of stage 2, confirmed. At ₹658 it trades −3.9% versus its 200-day average and sits at 54% of its 52-week range (₹558–₹743).
Against the market, two honest reads. Cumulative: over the last 5.5 years the stock moved +145% while the NIFTY 500 moved +87% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Jubilant Ingrevia Ltd's story is not scored yet against the markers our research file set on 6 September 2026. Where it sits in its own cycle: mixed. Marker count: 12 not due yet.
The test written in advance. Large CDMO contract quarterly volumes and EBITDA contribution (company disclosure) — Another pause, a make-whole invocation, or continued 'no firm timeline' — Large CDMO contract quarterly volumes and EBITDA contribution (company disclosure) Q1 FY27: partial volumes, EBITDA-positive but unquantified; innovator paused part of the volume by FY27-Q2 (call expected late Oct 2026).
The test written in advance. FY27 EBITDA guidance of Rs 750-800 crore (quarterly run-rate) — Quarters well below Rs 200cr, forcing the guide off the 800 end — FY27 EBITDA guidance of Rs 750-800 crore (quarterly run-rate) Q1 FY27 EBITDA Rs 209cr; H1 expected around Rs 400cr-plus, roughly Rs 200cr per quarter (Varun Gupta) by Each quarter through FY27-Q4.
The test written in advance. Vitamin B3 / nicotinamide pricing and Nutrition segment EBITDA — China nicotinamide prices reverse the spike and Nutrition EBITDA falls back toward the Rs 23-25cr range of Q3 FY26 — Vitamin B3 / nicotinamide pricing and Nutrition segment EBITDA by FY27-Q2 and FY27-Q3.
Lever 2 · Value-added mix — BUILDING. Specialty FY26 revenue Rs 1,937cr (+7%), EBITDA Rs 510cr (+21%); specialty+nutrition 85%+ of EBITDA; Specialty margins 25-27% across six quarters (Q3 FY26 was 25.3%); Nutrition Q1 FY27 EBITDA Rs 36cr at 15%. What proves it keeps working: 'Portfolio mix moving in favor of specialty and nutrition, contributing almost 85% plus of overall EBITDA. Specialty EBITDA almost doubling in last 2 years.' (2026-05-26). It stops working if Q3 FY26 Specialty margin was 25.3% ('above 25%'), not 27%; the 85% share oscillates with the acetyls cycle (87% in Q3 FY25 vs 73% in Q2 FY25) and rose partly because Chemical Intermediates EBITDA fell 39% over 9M FY25 (B2, bear_wins).
Lever 6 · Order-book wins — BUILDING. $300m over 5 years = $60m a year, close to Rs 500cr annualised; supplies began March 2026; Q1 FY27 partial volumes, EBITDA-positive but unquantified; 25+ confirmed molecules, Rs 3,500cr+ peak-revenue funnel. What proves it keeps working: 'In the unforeseen circumstances of they not giving us any volume, we have full protection, which will more than cover for whatever EBITDA expectations we have communicated to the markets.' (2026-07-23).
Lever 4 · Paying down debt — ACTIVE. Net debt/EBITDA 1.36x (Dec 2024) to 0.99x (Mar 2026); derived interest cover 5.49x (Mar 2024) to 8.02x (Mar 2026); derived debt-to-equity 0.2534. What proves it keeps working: 'Net debt by EBITDA improved to 0.99x. Our net debt has reduced by 11% in 2026.' (2026-05-26). It stops working if Gross borrowings rose Rs 740cr to Rs 792cr; the improvement came from cash doubling (Rs 78.8cr to Rs 189.9cr) and EBITDA lifting the denominator, not repayment — but the financial benefit itself stands (B8, bull_wins); no operating credit taken.
Sources: Y-skill two-pass review (glm-5.3:cloud), rubric Y-OL-1, question set YQ-2, 2026-09-06; Instruction bundle sha d59418593786aba12de34a87b5c26bfbc882f5bf32d1fdaa501a2c38c970c592. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Jubilant Ingrevia Ltd reported ₹1,300 Cr of revenue in the Jun 26 quarter, +25.2% year on year. That is the 2nd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹4,388 Cr. The last four reported quarters add to ₹4,651 Cr.
FY26 revenue came in at ₹4,388 Cr (+5.0% on the year). The latest quarter (Jun 26) printed ₹1,300 Cr, +25.2% year on year — the 2nd consecutive quarter of year-over-year growth.
Acceleration check: trailing-twelve-month revenue grew +11.0% over the last 4 quarters against +6.7%/yr over the last 8 — accelerating; TTM profit +11.2% vs +33.0%/yr — rolling over.
FY26-Q4. Revenue 1179 cr, PAT 86 cr, OPM 13.8% — this review produced no quarter-level why; see the levers.
FY27-Q1. Revenue 1300 cr, PAT 106 cr, OPM 15.3% — this review produced no quarter-level why; see the levers.
Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Jubilant Ingrevia Ltd's operating margin is 15.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 10.0% to 17.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 15.0%, +1.0 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 10.0%–17.0%.
Why the margin moved: operating margin went +1.6 pp year on year while gross margin went +0.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
FY26-Q4. Revenue 1179 cr, PAT 86 cr, OPM 13.8% — this review produced no quarter-level why; see the levers.
FY27-Q1. Revenue 1300 cr, PAT 106 cr, OPM 15.3% — this review produced no quarter-level why; see the levers.
Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Jubilant Ingrevia Ltd earned ₹106 Cr of net profit in the Jun 26 quarter, +41.3% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹278 Cr. That is 8.2% of the quarter's revenue. The same quarter a year earlier earned ₹75.0 Cr.
Jun 26 profit was ₹106 Cr, +41.3% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹278 Cr (+10.8%).
Why profit moved: revenue contributed +25.2% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +10.6% vs revenue +11.0%. Profit and revenue are moving roughly in step.
FY26-Q4. Revenue 1179 cr, PAT 86 cr, OPM 13.8% — this review produced no quarter-level why; see the levers.
FY27-Q1. Revenue 1300 cr, PAT 106 cr, OPM 15.3% — this review produced no quarter-level why; see the levers.
Why-sources: our stock research file (6 September 2026) and the company’s own results for those quarters.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 205% of Jubilant Ingrevia Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹524 Cr of operating cash against ₹278 Cr of profit. After ₹406 Cr of capital spending, ₹118 Cr was left as free cash.
FY26: operating cash of ₹524 Cr against reported profit of ₹278 Cr, leaving free cash of ₹118 Cr after ₹406 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 205% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 205%: the cash cycle tightened 112 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 3.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Jubilant Ingrevia Ltd's cash conversion cycle runs 55 days in FY26, down from 167 days in FY21. Capital spending ran ₹1,435 Cr over the last 3 years. At FY26 sales of ₹4,388 Cr each day of that cycle holds about ₹12.0 Cr, so roughly ₹661 Cr sits inside the business at any moment.
FY26: debtors at 65 days, inventory at 140 days — roughly 4.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 55 days, tighter than FY21's 167.
The full loop: cash goes out to suppliers and production on day 0; stock waits 140 days to sell; customers pay about 65 days after that; and suppliers themselves are paid at 150 days — netting out to the 55-day cycle.
In money terms: at FY26 sales of ₹4,388 Cr, each day of the cycle holds about ₹12.0 Cr — so the 55-day loop keeps roughly ₹661 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,435 Cr over the last 3 fiscal years against ₹469 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹154 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Jubilant Ingrevia Ltd earns a ROCE of 11% in FY26. That is up from a trough of 8% in FY21. Return on invested capital clears the cost of that capital by −3.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.3% net margin on 0.80× asset turns.
FY26 ROCE is 11%, recovered from a FY21 trough of 8% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 6.3% net margin × 0.80× asset turns × 1.75× balance-sheet leverage ≈ 8.8% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 8.8% − 12.0% = a −3.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Jubilant Ingrevia Ltd carries total debt of ₹792 Cr against shareholder equity of ₹3,126 Cr as of Jun 26, a debt-to-equity of 0.25 — effectively unlevered. On the annual view that ratio went from 0.10 in FY22 to 0.25 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of ₹792 Cr against shareholder equity of ₹3,126 Cr — a debt-to-equity of 0.25. On the annual view, debt-to-equity went from 0.10 (FY22) to 0.25 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 10.9 points of Jubilant Ingrevia Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 25.0% of the company. Promoters moved −6.3 points over the same window, to 45.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +10.9 points over 8 quarters to 25.0%; Promoters: −6.3 points over 8 quarters to 45.2%; Foreign institutions: −0.1 points over 8 quarters to 6.5%.
Why the register moved: domestic institutions drove it (+10.9 points), absorbed on the other side by promoters (−6.3 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Jubilant Ingrevia Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Jubilant Ingrevia Ltd trades at 33.0× P/E, mid-range by its own standards (39th percentile). Its long-run median P/E is 37.1×, measured across 5.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 33.0× is mid-range by its own standards (39th percentile), against a long-run median of 37.1× measured over 5.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +10.7% against a −7.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −1.3%/yr price move, ~+38.0%/yr came from earnings growth and ~−39.3 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Jubilant Ingrevia Ltd was paying for profit growth of about 22.1% a year. Today the market pays 33.0× P/E, the 39th percentile of its own 5-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is the whole of what a buyer is backing.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Jubilant Ingrevia Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +59.2% at its peak to +11.2% but is still expanding, ROCE holding at 12.3%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.0% | −2.8% | +45.0% | — |
| Profit | +10.8% | −3.4% | +38.8% | — |
| EPS | +10.7% | −3.3% | +38.6% | — |
| Share price | −7.1% | +8.5% | −1.3% | — |
4-Factor Sector Score
50.5/100 — rank 11 of 24 in Pesticides/Agrochemicals · 93% evidence confidence
Jubilant Ingrevia Ltd scores 50.5 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 19 + 10.6 + 6.1 + 14.8 = 50.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Quarterly scorecard
12 markers came out of our Jubilant Ingrevia Ltd research file of 6 September 2026, and each results season scores every one of them. No results season has been scored against them yet. A row is permanent: a miss stays on the record after it is fixed.
| Marker | The bar | Where it stands | Score |
|---|---|---|---|
| M1 | Large CDMO contract quarterly volumes and EBITDA contribution (company disclosure) — Another pause, a make-whole invocation, or continued 'no firm timeline' | Not checked yet. | PENDING |
| M10 | Chemical Intermediates segment EBITDA sustainability | Not checked yet. | PENDING |
| M11 | Gajraula multipurpose plant commissioning | Not checked yet. | PENDING |
| M12 | Debtor days (receivables collection) | Not checked yet. | PENDING |
| M2 | FY27 EBITDA guidance of Rs 750-800 crore (quarterly run-rate) — Quarters well below Rs 200cr, forcing the guide off the 800 end | Not checked yet. | PENDING |
| M3 | Vitamin B3 / nicotinamide pricing and Nutrition segment EBITDA — China nicotinamide prices reverse the spike and Nutrition EBITDA falls back toward the Rs 23-25cr range of Q3 FY26 | Not checked yet. | PENDING |
| M4 | Chemical Intermediates segment EBITDA sustainability — CI EBITDA collapses back toward the Rs 17-22cr range, confirming the pass-through reading (Chemical Intermediates segment EBITDA sustainability) | Not checked yet. | PENDING |
| M5 | Gajraula multipurpose plant commissioning — A slip beyond Q4 FY27 (Gajraula multipurpose plant commissioning) | Not checked yet. | PENDING |
| M6 | Debtor days (receivables collection) — A further rise above 65 days, meaning growth is funding customer credit (Debtor days (receivables collection)) | Not checked yet. | PENDING |
| M7 | Large CDMO contract quarterly volumes and EBITDA contribution (company disclosure) | Not checked yet. | PENDING |
| M8 | FY27 EBITDA guidance of Rs 750-800 crore (quarterly run-rate) | Not checked yet. | PENDING |
| M9 | Vitamin B3 / nicotinamide pricing and Nutrition segment EBITDA | Not checked yet. | PENDING |
Said versus delivered
What Jubilant Ingrevia Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Full-Year EBITDA Guidance Framework Changed · 23 July 2026. In May 2026, management explicitly framed the full-year EBITDA outlook as at least 20% growth, following FY26 EBITDA of Rs. 510 crore; the February 2026 call used the same at-least-20% multiyear framework. In Jul 2026, management referred to full-year guidance of 750 to 800 crores, which implies roughly 47%-57% growth over FY26 EBITDA, a material step-up that was not reconciled with the prior call guidance. Management attributed the range to an intervening Bharuch discussion, but did not explain the change in the provided calls.
🚨 Major CDMO Contract Volume Certainty · 26 May 2026. In the Oct 2025 call, management expressed absolute certainty regarding the volume ramp of their $300 million major agro innovator contract, claiming it would run at 100% potential from the very first day. However, in the May 2026 call, management revealed that the customer is facing financial difficulties and the future volume scenarios are suddenly unclear, forcing them to rely on contractual "make whole" defensive clauses rather than guaranteed operational scale.
🚨 Smaller Agro CDMO Contract Growth Downgrade · 26 May 2026. Through Oct 2025, management was highly confident about the scale-up of their smaller, executed agro CDMO contract, explicitly stating they had visibility for >50% growth the following year. By May 2026, management completely walked back this growth visibility, stating volumes were unconfirmed and that they are only hoping revenues remain flat year-over-year.
🚨 Walk-back on CDMO Contract Ramp-up · 5 February 2026. During the October 2025 call, management confidently asserted that the major Agro CDMO contract would start serving in Q4 at '100% potential from day 1.' In the February 2026 call, this stance shifted significantly to uncertainty regarding volumes ('quantum-wise, we will have to see') and a target of only starting dispatches by 'mid to late March,' implying the full quarter benefit was missed. Earlier call (Oct 2025): “We maintain to start serving this big contract starting next quarter... The big molecule that we are starting in January, February will start from 100% potential from day 1 itself, which is the agreement with the customer.” Later call (Feb 2026): “Quantum-wise, we will have to see... We are trying our best to maximize the production within this quarter... planning to start supplies hopefully by mid to late March.”
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Bayer CropScience LtdBAYERCROP | 71.8/100Favorable setup94% evidence | BASING | 22.9/35 Revenue -2.8% · PAT 23.8% · OPM change 2 pp 100% evidence | 21.2/25 ROCE 29.1% · OPM 20% 100% evidence | 14.7/20 P/E 24.4× · PEG 1.28 100% evidence | 13.0/20 RS sector 9.4% · RS bench -11% · 1Y -21.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.9 + 21.2 + 14.7 + 13 = 71.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Titan Biotech Ltd524717 | 68.9/100Favorable setup82% evidence | ASLEEP | 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 2 pp 95% evidence | 20.1/25 ROCE 22.8% · OPM 21% 76% evidence | 5.7/20 P/E 53.3× · PEG — 50% evidence | 14.0/20 RS sector 35.7% · RS bench 34.4% · 1Y 213.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 20.1 + 5.7 + 14 = 68.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Sharda Cropchem LtdSHARDACROP | 64.7/100Mixed-positive evidence100% evidence | BASING | 24.2/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 100% evidence | 19.6/25 ROCE 30.2% · OPM 17% 100% evidence | 18.7/20 P/E 11× · PEG 0.26 100% evidence | 2.2/20 RS sector -14.6% · RS bench -15.4% · 1Y -16.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 19.6 + 18.7 + 2.2 = 64.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.6% and the one-year return is -16.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 4Dharmaj Crop Guard LtdDHARMAJ | 63.2/100Mixed-positive evidence74% evidence | BASING | 21.1/35 Revenue 8.5% · PAT 13.2% · OPM change 1 pp 95% evidence | 15.9/25 ROCE 16.8% · OPM 15% 95% evidence | 10.9/20 P/E 15.1× · PEG — 15% evidence | 15.3/20 RS sector 5% · RS bench 4.5% · 1Y -27.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.1 + 15.9 + 10.9 + 15.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Punjab Chemicals & Crop Protection LtdPUNJABCHEM | 60.5/100Mixed-positive evidence81% evidence | BREAKING OUT | 23.4/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 17.9/25 ROCE 18.6% · OPM 12% 95% evidence | 11.6/20 P/E 19.5× · PEG — 50% evidence | 7.6/20 RS sector -6.2% · RS bench -5.8% · 1Y -4.2%5 of 10 weeks ahead 70% evidence |
| Exact sum: 23.4 + 17.9 + 11.6 + 7.6 = 60.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 56.9/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.3/35 Revenue 48.4% · PAT 81.5% · OPM change 1 pp 95% evidence | 14.8/25 ROCE 19.6% · OPM 11% 95% evidence | 10.8/20 P/E 15.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence |
| Exact sum: 21.3 + 14.8 + 10.8 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7India Pesticides LtdIPL | 52.9/100Mixed-positive evidence81% evidence | BASING | 20.1/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.7/25 ROCE 16.6% · OPM 14% 95% evidence | 14.1/20 P/E 14.3× · PEG — 50% evidence | 5.0/20 RS sector -11.9% · RS bench -17.5% · 1Y -35.3%1 of 11 weeks ahead 70% evidence |
| Exact sum: 20.1 + 13.7 + 14.1 + 5 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Bhagiradha Chemicals & Industries LtdBHAGCHEM | 51.9/100Mixed-positive evidence100% evidence | ASLEEP | 29.1/35 Revenue 33.7% · PAT 100% · OPM change 9 pp 100% evidence | 7.0/25 ROCE 4.5% · OPM 16% 100% evidence | 1.6/20 P/E 122× · PEG 8.06 100% evidence | 14.2/20 RS sector 9.1% · RS bench 7.6% · 1Y -4.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 7 + 1.6 + 14.2 = 51.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Rallis India LtdRALLIS | 50.9/100Mixed-positive evidence94% evidence | BASING | 20.4/35 Revenue 4.4% · PAT 24.4% · OPM change 2 pp 100% evidence | 10.6/25 ROCE 14.1% · OPM 18% 100% evidence | 11.5/20 P/E 17.2× · PEG 2.15 100% evidence | 8.4/20 RS sector -1.8% · RS bench -19% · 1Y -43.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 10.6 + 11.5 + 8.4 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Astec Lifesciences LtdASTEC | 50.9/100Mixed-positive evidence69% evidence | BASING | 23.9/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 3.2/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.8/20 RS sector 5.1% · RS bench 3.6% · 1Y -17.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 3.2 + 10 + 13.8 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Jubilant Ingrevia Ltdthis pageJUBLINGREA | 50.5/100Mixed-positive evidence93% evidence | TURNING | 19.0/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.4% · OPM 15% 100% evidence | 6.1/20 P/E 33× · PEG 2.41 65% evidence | 14.8/20 RS sector 0.7% · RS bench -0.6% · 1Y -8.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 10.6 + 6.1 + 14.8 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Sumitomo Chemical India LtdSUMICHEM | 46.2/100Mixed-negative evidence94% evidence | FADING | 12.6/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 5.5/20 P/E 41.6× · PEG 4 100% evidence | 9.1/20 RS sector -8.2% · RS bench 3.2% · 1Y -16.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 19 + 5.5 + 9.1 = 46.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13NACL Industries LtdNACLIND | 45.9/100Mixed-negative evidence100% evidence | ASLEEP | 29.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 3.9/25 ROCE 8.1% · OPM 11% 100% evidence | 3.7/20 P/E 142× · PEG 2.02 100% evidence | 9.2/20 RS sector -4.3% · RS bench -5.8% · 1Y -35%7 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 3.9 + 3.7 + 9.2 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Meghmani Organics LtdMOL | 45.8/100Mixed-negative evidence74% evidence | BREAKING OUT | 20.8/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 7.8/25 ROCE 6.7% · OPM 18% 95% evidence | 9.4/20 P/E 24.8× · PEG — 15% evidence | 7.8/20 RS sector -33.7% · RS bench 7.6% · 1Y -22%7 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 7.8 + 9.4 + 7.8 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Excel Industries LtdEXCELINDUS | 42.8/100Mixed-negative evidence74% evidence | TURNING | 12.4/35 Revenue 5.5% · PAT -20.4% · OPM change 0 pp 95% evidence | 10.3/25 ROCE 6.2% · OPM 14% 95% evidence | 10.4/20 P/E 17.3× · PEG — 15% evidence | 9.7/20 RS sector -4.6% · RS bench 1.7% · 1Y -15.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 10.3 + 10.4 + 9.7 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16UPL LtdUPL | 42.2/100Mixed-negative evidence91% evidence | BASING | 17.1/35 Revenue 12.9% · PAT 98.4% · OPM change -2 pp 74% evidence | 8.3/25 ROCE 10.1% · OPM 13% 100% evidence | 12.2/20 P/E 24.5× · PEG 0.5 100% evidence | 4.6/20 RS sector -11.6% · RS bench -12.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 8.3 + 12.2 + 4.6 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Bharat Rasayan LtdBHARATRAS | 41.9/100Mixed-negative evidence87% evidence | ASLEEP | 10.8/35 Revenue -5.2% · PAT 3.6% · OPM change -3 pp 95% evidence | 13.6/25 ROCE 16% · OPM 15% 95% evidence | 14.4/20 P/E 13.2× · PEG — 50% evidence | 3.1/20 RS sector -32.8% · RS bench -34% · 1Y -53.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.8 + 13.6 + 14.4 + 3.1 = 41.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Epigral LtdEPIGRAL | 41.2/100Mixed-negative evidence94% evidence | TURNING | 7.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.5/25 ROCE 15.5% · OPM 25% 100% evidence | 14.4/20 P/E 18× · PEG 0.43 100% evidence | 4.8/20 RS sector -32.9% · RS bench -6.6% · 1Y -35.9%1 of 10 weeks ahead 70% evidence |
| Exact sum: 7.5 + 14.5 + 14.4 + 4.8 = 41.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Dhanuka Agritech LtdDHANUKA | 40.8/100Mixed-negative evidence100% evidence | BASING | 6.6/35 Revenue -5.6% · PAT -12.1% · OPM change -4 pp 100% evidence | 16.2/25 ROCE 23.8% · OPM 12% 100% evidence | 11.4/20 P/E 16.3× · PEG 1.72 100% evidence | 6.6/20 RS sector -11% · RS bench -12.4% · 1Y -38.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.6 + 16.2 + 11.4 + 6.6 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Best Agrolife LtdBESTAGRO | 40.0/100Mixed-negative evidence87% evidence | TURNING | 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.1/25 ROCE 5.2% · OPM 20% 95% evidence | 8.8/20 P/E 22.8× · PEG — 50% evidence | 14.2/20 RS sector -0.4% · RS bench -1.8% · 1Y -27.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 9.1 + 8.8 + 14.2 = 40 · Decision use: Price leads the evidence: RS versus the benchmark is -1.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Insecticides India LtdINSECTICID | 37.6/100Mixed-negative evidence87% evidence | BASING | 10.7/35 Revenue 1.3% · PAT -16.7% · OPM change -1 pp 95% evidence | 10.8/25 ROCE 15.8% · OPM 11% 95% evidence | 11.5/20 P/E 14.2× · PEG — 50% evidence | 4.6/20 RS sector -6.7% · RS bench -8% · 1Y -23.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 10.8 + 11.5 + 4.6 = 37.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22P I Industries LtdPIIND | 35.3/100Mixed-negative evidence94% evidence | BASING | 4.7/35 Revenue -16.6% · PAT -27.8% · OPM change -5 pp 100% evidence | 13.8/25 ROCE 15% · OPM 22% 100% evidence | 9.5/20 P/E 31.7× · PEG 1.71 100% evidence | 7.3/20 RS sector -3.4% · RS bench -25.1% · 1Y -38.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 4.7 + 13.8 + 9.5 + 7.3 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Heranba Industries LtdHERANBA | 28.0/100Adverse evidence77% evidence | BASING | 8.9/35 Revenue -2.6% · PAT -80% · OPM change 5.9 pp 95% evidence | 2.8/25 ROCE -1.7% · OPM 12.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.3/20 RS sector -19% · RS bench -20.3% · 1Y -48.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.9 + 2.8 + 10 + 6.3 = 28 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24GSP Crop Science LtdGSPCROP | 47.7/100Thin evidence · provisional38% evidence | BREAKING OUT | 14.2/35 Revenue — · PAT — · OPM change 0 pp 45% evidence | 13.6/25 ROCE 18.9% · OPM 11% 76% evidence | 9.9/20 P/E 21× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 9 weeks ahead 0% evidence |
| Exact sum: 14.2 + 13.6 + 9.9 + 10 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Jubilant Ingrevia Ltd's share price today?
Jubilant Ingrevia Ltd trades at ₹658, −7.1% over the past year. The company is valued at ₹10,487 Cr. The stock sits at 54% of its 52-week range of ₹558–₹743, −3.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 8 weeks in. — as of 11 September 2026.
What were Jubilant Ingrevia Ltd's latest quarterly results?
Jubilant Ingrevia Ltd reported revenue of ₹1,300 Cr and net profit of ₹106 Cr for the Jun 26 quarter. Revenue rose 25.2% and profit rose 41.3% year on year. Earnings per share were ₹6.64. The operating margin was 15.0%, 1.0 pp higher than a year earlier. — as of 11 September 2026.
What is Jubilant Ingrevia Ltd's revenue?
Jubilant Ingrevia Ltd reported revenue of ₹1,300 Cr in the Jun 26 quarter, +25.2% year on year. For the full FY26 fiscal year, revenue was ₹4,388 Cr (+5.0%). — as of 11 September 2026.
What is Jubilant Ingrevia Ltd's profit?
Jubilant Ingrevia Ltd earned ₹106 Cr of net profit in the Jun 26 quarter, +41.3% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹278 Cr. The operating margin ran 15.0% in the latest quarter. — as of 11 September 2026.
What is Jubilant Ingrevia Ltd's market cap?
Jubilant Ingrevia Ltd's market capitalisation is ₹10,487 Cr at a share price of ₹658. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Jubilant Ingrevia Ltd's P/E ratio?
Jubilant Ingrevia Ltd trades at a P/E of 33.0×, at the 39th percentile of its own 5-year range, against a long-run median of 37.1×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Jubilant Ingrevia Ltd pay a dividend?
Yes — Jubilant Ingrevia Ltd's dividend payout was 28% of profit in FY26, and it recorded a payout in 6 of its last 7 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Jubilant Ingrevia Ltd overvalued?
On its own history, Jubilant Ingrevia Ltd looks mid-range: its P/E of 33.0× sits at the 39th percentile of its 5-year range (long-run median 37.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Jubilant Ingrevia Ltd growing?
Yes — Jubilant Ingrevia Ltd is growing: latest-quarter revenue +25.2% year on year, profit +41.3%, and the margin +1.0 pp at 15.0%. The earnings engine currently reads: improving — as of 11 September 2026.
How is Jubilant Ingrevia Ltd performing?
Jubilant Ingrevia Ltd is in a confirmed uptrend, 8 weeks in. Its latest quarter's revenue rose 25.2% and profit rose 41.3% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Jubilant Ingrevia Ltd in?
Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +59.2% at its peak to +11.2% but is still expanding, ROCE holding at 12.3%. The read comes from the last 12 quarters of growth (revenue growth +11.0% latest, profit growth +11.2% latest, eps growth +11.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Jubilant Ingrevia Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 8 of stage 2), trading −3.9% versus its 200-day average and at 54% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Jubilant Ingrevia Ltd beating the market?
On recent form, yes — Jubilant Ingrevia Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.5 years the stock moved +145% against the NIFTY 500's +87% — ahead of the index over the full window. — as of 11 September 2026.
Will Jubilant Ingrevia Ltd's share price go up?
This page publishes no price forecast for Jubilant Ingrevia Ltd. What it measures instead: the share price is ₹658, the price is in a confirmed uptrend 8 weeks in. Its P/E of 33.0× sits at the 39th percentile of its own 5-year range. — as of 11 September 2026.
Who owns Jubilant Ingrevia Ltd?
Promoters hold 45.2% of Jubilant Ingrevia Ltd, foreign institutions 6.5%, domestic institutions 25.0% and the public 22.3% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 10.9 points over 8 quarters. — as of 11 September 2026.
Does Jubilant Ingrevia Ltd have too much debt?
No — Jubilant Ingrevia Ltd's debt-to-equity is 0.25, and operating profit covers the interest bill 12×. FY26 borrowings were ₹792 Cr against equity of ₹3,126 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Jubilant Ingrevia Ltd's capex?
Jubilant Ingrevia Ltd spent ₹1,435 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹406 Cr, with ₹154 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Jubilant Ingrevia Ltd's cash flow?
Jubilant Ingrevia Ltd generated ₹524 Cr of operating cash flow in FY26 and ₹118 Cr of free cash flow after ₹406 Cr of capital spending. Reported profit that year was ₹278 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Jubilant Ingrevia Ltd's profit real cash?
Yes — over the last 3 fiscal years, 205% of Jubilant Ingrevia Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹524 Cr against reported profit of ₹278 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Jubilant Ingrevia Ltd in its business cycle?
Jubilant Ingrevia Ltd's FY26 operating margin was 13.0%, against a 6-year band of 10.0%–17.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Jubilant Ingrevia Ltd's price assume?
At its price on 13 June 2026, Jubilant Ingrevia Ltd was priced for profit growth of about 22.1% a year. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Jubilant Ingrevia Ltd story?
The sharpest disagreement: Promoters moved −6.3 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Jubilant Ingrevia Ltd a stock worth studying right now?
This is not investment advice. The machine read: Jubilant Ingrevia Ltd's earnings have outrun its stock. EPS grew +10.7% in a year against a −7.1% price move. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!